Cargando…

Survival outcomes and epidemiology of Merkel cell carcinoma of the lower limb and hip: A Surveillance, Epidemiology, and End Results analysis 2000-2018

BACKGROUND: Merkel cell carcinoma of lower limb and hip skin is a rare skin tumor that has a high recurrence rate. OBJECTIVE: To assess epidemiology and survival outcomes of the lower limb and hip Merkel cell carcinoma, which are less addressed in the literature. METHODS: The Surveillance, Epidemiol...

Descripción completa

Detalles Bibliográficos
Autores principales: Scampa, Matteo, Merat, Rastine, Tzika, Evangelia, Kalbermatten, Daniel F., Oranges, Carlo M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873923/
https://www.ncbi.nlm.nih.gov/pubmed/35243404
http://dx.doi.org/10.1016/j.jdin.2021.12.010
_version_ 1784657569176879104
author Scampa, Matteo
Merat, Rastine
Tzika, Evangelia
Kalbermatten, Daniel F.
Oranges, Carlo M.
author_facet Scampa, Matteo
Merat, Rastine
Tzika, Evangelia
Kalbermatten, Daniel F.
Oranges, Carlo M.
author_sort Scampa, Matteo
collection PubMed
description BACKGROUND: Merkel cell carcinoma of lower limb and hip skin is a rare skin tumor that has a high recurrence rate. OBJECTIVE: To assess epidemiology and survival outcomes of the lower limb and hip Merkel cell carcinoma, which are less addressed in the literature. METHODS: The Surveillance, Epidemiology, and End Results database was searched for all cases of skin Merkel cell carcinoma between 2000 and 2018. Demographic and clinicopathologic features were compared between lower limb and other skin localizations using the t test or χ(2) test. The overall survival (OS) of lower limb Merkel cell carcinoma was calculated using the Kaplan-Meier method. Subgroups were compared using the log rank test. Multivariate cox regression was used to identify independent prognostic factors. RESULTS: In total, 976 patients were identified. The mean age was 72.7 years. The median OS was 68 months, better than that of other localizations. Older age, regional lymph node, and distant metastasis were associated with low OS. Surgery with >1-cm margins, when associated with radiotherapy, had the best OS. Age, tumor size, lymph node status, presence of metastasis, and treatment sequence were identified as independent prognostic factors. CONCLUSION: Lower limb and hip Merkel cell carcinomas have better OS than tumors in other skin localizations. In this dataset, the best OS was ensured using surgery with >1-cm margins and adjuvant radiotherapy.
format Online
Article
Text
id pubmed-8873923
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88739232022-03-02 Survival outcomes and epidemiology of Merkel cell carcinoma of the lower limb and hip: A Surveillance, Epidemiology, and End Results analysis 2000-2018 Scampa, Matteo Merat, Rastine Tzika, Evangelia Kalbermatten, Daniel F. Oranges, Carlo M. JAAD Int Original Article BACKGROUND: Merkel cell carcinoma of lower limb and hip skin is a rare skin tumor that has a high recurrence rate. OBJECTIVE: To assess epidemiology and survival outcomes of the lower limb and hip Merkel cell carcinoma, which are less addressed in the literature. METHODS: The Surveillance, Epidemiology, and End Results database was searched for all cases of skin Merkel cell carcinoma between 2000 and 2018. Demographic and clinicopathologic features were compared between lower limb and other skin localizations using the t test or χ(2) test. The overall survival (OS) of lower limb Merkel cell carcinoma was calculated using the Kaplan-Meier method. Subgroups were compared using the log rank test. Multivariate cox regression was used to identify independent prognostic factors. RESULTS: In total, 976 patients were identified. The mean age was 72.7 years. The median OS was 68 months, better than that of other localizations. Older age, regional lymph node, and distant metastasis were associated with low OS. Surgery with >1-cm margins, when associated with radiotherapy, had the best OS. Age, tumor size, lymph node status, presence of metastasis, and treatment sequence were identified as independent prognostic factors. CONCLUSION: Lower limb and hip Merkel cell carcinomas have better OS than tumors in other skin localizations. In this dataset, the best OS was ensured using surgery with >1-cm margins and adjuvant radiotherapy. Elsevier 2022-02-23 /pmc/articles/PMC8873923/ /pubmed/35243404 http://dx.doi.org/10.1016/j.jdin.2021.12.010 Text en © 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Scampa, Matteo
Merat, Rastine
Tzika, Evangelia
Kalbermatten, Daniel F.
Oranges, Carlo M.
Survival outcomes and epidemiology of Merkel cell carcinoma of the lower limb and hip: A Surveillance, Epidemiology, and End Results analysis 2000-2018
title Survival outcomes and epidemiology of Merkel cell carcinoma of the lower limb and hip: A Surveillance, Epidemiology, and End Results analysis 2000-2018
title_full Survival outcomes and epidemiology of Merkel cell carcinoma of the lower limb and hip: A Surveillance, Epidemiology, and End Results analysis 2000-2018
title_fullStr Survival outcomes and epidemiology of Merkel cell carcinoma of the lower limb and hip: A Surveillance, Epidemiology, and End Results analysis 2000-2018
title_full_unstemmed Survival outcomes and epidemiology of Merkel cell carcinoma of the lower limb and hip: A Surveillance, Epidemiology, and End Results analysis 2000-2018
title_short Survival outcomes and epidemiology of Merkel cell carcinoma of the lower limb and hip: A Surveillance, Epidemiology, and End Results analysis 2000-2018
title_sort survival outcomes and epidemiology of merkel cell carcinoma of the lower limb and hip: a surveillance, epidemiology, and end results analysis 2000-2018
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873923/
https://www.ncbi.nlm.nih.gov/pubmed/35243404
http://dx.doi.org/10.1016/j.jdin.2021.12.010
work_keys_str_mv AT scampamatteo survivaloutcomesandepidemiologyofmerkelcellcarcinomaofthelowerlimbandhipasurveillanceepidemiologyandendresultsanalysis20002018
AT meratrastine survivaloutcomesandepidemiologyofmerkelcellcarcinomaofthelowerlimbandhipasurveillanceepidemiologyandendresultsanalysis20002018
AT tzikaevangelia survivaloutcomesandepidemiologyofmerkelcellcarcinomaofthelowerlimbandhipasurveillanceepidemiologyandendresultsanalysis20002018
AT kalbermattendanielf survivaloutcomesandepidemiologyofmerkelcellcarcinomaofthelowerlimbandhipasurveillanceepidemiologyandendresultsanalysis20002018
AT orangescarlom survivaloutcomesandepidemiologyofmerkelcellcarcinomaofthelowerlimbandhipasurveillanceepidemiologyandendresultsanalysis20002018